Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Canopy Growth Corp T.WEED

Alternate Symbol(s):  T.WEED.DB | CGC

Canopy Growth Corporation is a cannabis company. It delivers innovative products with a focus on premium and mainstream cannabis brands, including Doja, 7ACRES, Tweed, and Deep Space, in addition to category-defining vaporizer technology made in Germany by Storz & Bickel. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. International markets cannabis segment includes the production, distribution, and sale of a range of cannabis and hemp products internationally. Storz & Bickel segment includes the production, distribution, and sale of vaporizers. This Works segment includes the production, distribution and sale of beauty, skincare, wellness and sleep products.


TSX:WEED - Post by User

Bullboard Posts
Comment by watchmeplzon Mar 07, 2016 1:43pm
94 Views
Post# 24630843

RE:RE:RE:Canada marijuana firms say illegal rivals costing them custo

RE:RE:RE:Canada marijuana firms say illegal rivals costing them custoYes lets talk about a valuation. Let's say you get lucky and revenue 12 Million a year. At a 300 million m/c value, your paying 25x SALES! Are you kidding me? Slightly overvalued? Landslide overvalued. That means, they have to sell 25x more, just to have a normal 1x sales valuation. Lets not even get into the EBITDA/Net valuation because your losing 3 Million a quarter. Plus with all new competition... Come on buddy, get real. If the company survives your light years away from this valuation even to be close to making sense. AND no one is to say the new ruling in 6 months wont keep and include the MMAR people, nice try.
endofdays7 wrote:
lol buddy allard ruling stated patients don't have enough access to medicine why because we don't have enough access to them. 6 months to overhall mmpr to improve access for patients. Shoppers making inquiries with lps. We're going into storefronts bottom line. No one cares if we are slightly overvalued based on current numbers. We are paying a slight premium to get in on the ground floor before expansion of the medical system and eventually legalization. Your arguments lack any practical foresight. Your shorting! At least raise points reletice to future growth. Oh wait you can't lol because as far as markets go it's hard to find a business with better odds for serious growth then canopy and a few other my plays.


Bullboard Posts